$CYTR,,,I tried to copy the link but was unable:
Form DEF 14A CYTRX CORP For:
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
to be held on July 12, 2017
Notice is hereby given to the holders of common stock, $0.001 par value per share, of CytRx Corporation that the Annual Meeting of Stockholders will be held at the Hotel Bel Air, 701 Stone Canyon Road, Los Angeles, California, at 10:00 A.M., local time, on Wednesday, July 12, 2017 for the following purposes:
·
The election of one Class II director to serve until the 2020 Annual Meeting of Stockholders;
·
Approval of an amendment to our Restated Certificate of Incorporation to enable our board of directors in its discretion to effect a reverse stock split of our outstanding common stock at any time prior to next year's annual meeting of our stockholders in the range of between 1-for-3 and 1-for-8;
·
Approval of separate amendments to our 2008 Stock Incentive Plan to (x) fix the aggregate number of shares of our common stock subject to the 2008 Plan at 10,000,000 shares and (y) fix the limitation on awards of stock options during any twelve-month period to any one participant, which we refer to as the "Section 162(m) limitation," at 1,500,000 shares, in each case, subject to the approval of Proposal 2 relating to the reverse stock split and after giving effect to the reverse stock split, if any;
·
Approval of an amendment to our Restated Certificate of Incorporation to increase the total number of shares of all classes of stock that CytRx shall have the authority to issue up to Five Hundred Five Million (505,000,000), of which Five Hundred Million (500,000,000) shall be common stock, par value $0.001 per share, and Five Million (5,000,000) shall be preferred stock, par value $0.01 per share, which amendment will be effected only if Proposal 2 relating to the reverse stock split is not approved or the reverse stock split is not effected;
·
To recommend, by advisory vote, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers;
·
The advisory approval of the compensation of our named executive officers as disclosed in this Proxy Statement;
·
The ratification of the selection of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017; and
·
The transaction of such other business as may properly come before the Annual Meeting and at any postponement or adjournment thereof.
Only those stockholders of record at the close of business on May 12, 2017 are entitled to notice of and to vote at the Annual Meeting and at any postponement or adjournment thereof. A complete list of stockholders entitled to vote at the Annual Meeting will be available at the Annual Meeting.
By Order of the board of directors,
May 22, 2017
/s/ JOHN Y. CALOZ
John Y. Caloz
Chief Financial Officer
Form DEF 14A CYTRX CORP For:
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
to be held on July 12, 2017
Notice is hereby given to the holders of common stock, $0.001 par value per share, of CytRx Corporation that the Annual Meeting of Stockholders will be held at the Hotel Bel Air, 701 Stone Canyon Road, Los Angeles, California, at 10:00 A.M., local time, on Wednesday, July 12, 2017 for the following purposes:
·
The election of one Class II director to serve until the 2020 Annual Meeting of Stockholders;
·
Approval of an amendment to our Restated Certificate of Incorporation to enable our board of directors in its discretion to effect a reverse stock split of our outstanding common stock at any time prior to next year's annual meeting of our stockholders in the range of between 1-for-3 and 1-for-8;
·
Approval of separate amendments to our 2008 Stock Incentive Plan to (x) fix the aggregate number of shares of our common stock subject to the 2008 Plan at 10,000,000 shares and (y) fix the limitation on awards of stock options during any twelve-month period to any one participant, which we refer to as the "Section 162(m) limitation," at 1,500,000 shares, in each case, subject to the approval of Proposal 2 relating to the reverse stock split and after giving effect to the reverse stock split, if any;
·
Approval of an amendment to our Restated Certificate of Incorporation to increase the total number of shares of all classes of stock that CytRx shall have the authority to issue up to Five Hundred Five Million (505,000,000), of which Five Hundred Million (500,000,000) shall be common stock, par value $0.001 per share, and Five Million (5,000,000) shall be preferred stock, par value $0.01 per share, which amendment will be effected only if Proposal 2 relating to the reverse stock split is not approved or the reverse stock split is not effected;
·
To recommend, by advisory vote, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers;
·
The advisory approval of the compensation of our named executive officers as disclosed in this Proxy Statement;
·
The ratification of the selection of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017; and
·
The transaction of such other business as may properly come before the Annual Meeting and at any postponement or adjournment thereof.
Only those stockholders of record at the close of business on May 12, 2017 are entitled to notice of and to vote at the Annual Meeting and at any postponement or adjournment thereof. A complete list of stockholders entitled to vote at the Annual Meeting will be available at the Annual Meeting.
By Order of the board of directors,
May 22, 2017
/s/ JOHN Y. CALOZ
John Y. Caloz
Chief Financial Officer
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280
